期刊文献+

结直肠癌肝转移肝切除术后早期复发的危险因素 被引量:6

Risk factors for early recurrence after curative hepatectomy for colorectal cancer liver metastases
原文传递
导出
摘要 目的 探讨结直肠癌肝转移(CRLM)肝切除术后早期复发的危险因素.方法 通过收集2004年1月至2013年12月武汉大学中南医院肿瘤科行根治性肝切除术的CRLM患者的病例资料,分析临床、病理等因素对CRLM患者肝切除术后早期复发的影响.结果 共纳入78例行根治性肝切除术的CRLM患者,其中30例出现早期复发,肝转移灶数量≥3个的CRLM患者术后早期复发的发生率明显高于数目<3个的患者(60.0%比28.3%,P<0.05),肝转移数目≥3个与术后早期复发明显相关.结论 肝转移灶数目≥3个是肝切除术后早期复发的唯一独立危险因素,肝转移灶数目≥3个的患者早期复发的风险明显升高. Objective To investigate the risk factors for early recurrence after curative hepatectomy for colorectal cancer liver metastases (CRLM).Methods A retrospective analysis was performed on patients who underwent curative hepatectomy for CRLM between 2004 and 2013 in order to find out the clinical and pathological factors influencing early recurrence.Results A total of 78 patients were included,including 30 patients with early recurrence.Patients with three or more liver metastases had significantly earlier recurrence than those with less than three liver metastases (60.0% vs.28.3%,P <0.05).Early recurrence was significantly associated with three or more liver metastases.Conclusion The independent risk factor for early recurrence was the "number of liver metastases ≥ 3 ".Patients with three or more liver metastases had significantly higher risk of early recurrence.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2015年第7期1707-1709,共3页 Chinese Journal of Experimental Surgery
基金 国家自然科学基金资助项目(81072152) 湖北省自然科学基金资助项目(2009CD201) 湖北省卫生厅科研资助项目(2013.JX6B20)
关键词 结直肠癌肝转移 肝切除术 早期复发 危险因素 Colorectal liver metastases Curative hepatectomy Early recurrence Risk factors
  • 相关文献

参考文献11

  • 1Rastogi T, Hildesheim A, Sinha R. Opportunities for cancer epidemiolo- gy in developing countries[ J]. Nat Rev Cancer,200d ,4( 11 ) :909-917.
  • 2de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recur- rence following curative intent surgery for colorectal liver metastasis:an international multi-institutional analysis of 1669 patients [ J ]. Ann Surg ,2009,250 ( 3 ) :440-448.
  • 3Vigan6 L, Ferrero A, Lo Tesoriere R, et al. Liver surgery for colorectal metastases :results after 10 years of follow-up. Long-term survivors,late recurrences, and prognostic role of morbidity [ J ]. Ann Surg Oncol, 2008,15 (9) :2458-2464.
  • 4Takahashi S, Konishi M, Nakagohri T, et al. Short time to recurrence af- ter hepatic resection correlates with poor prognosis in eolorectal hepatic metastasis[J]. Jpn J Clin Oneol,2006,36(6) :368-375.
  • 5Yamashita Y, Adachi E, Tab Y, et al. Risk factors for early recurrence after curative hepateetamy for colorectal liver metastases [ J 1- Surg To- day,2011,41 (4) :526-532.
  • 6Vigan6 L, Capussotti L, Lapointe R, et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treat- ment. A l,iverMetSurvey-based study of 6,025 patients [ J ]. Ann Surg 0ncol,2014,21 (4) :1276-1286.
  • 7李华驰,刘佩,冯茂辉.结直肠癌肝转移的有效治疗策略[J].中华临床医师杂志(电子版),2014,8(23):109-115. 被引量:1
  • 8Nordlinger B, Sorbye H, Glimelius B, et al. Pefioperative FOLFOX4 Chemotherapy and surgery versus surgery alone for resectable liver me- tastases from colorectal cancer (EORTC40983) :long-term results of a randomize, controlled, phase 3 trial [ J ]. Lancet Oncol, 2013,14 ( 12 ) : 1208-1215.
  • 9Ribero D ,Viganb L,Amisano M ,et al. Prognostic factors after resection of colorectal liver metastases : from morphology to biology [ J ]. Future Onco1,2013,9( 1 ) :45-57.
  • 10Gruenberger B, Scheithauer W,Punzengruber R, et al. Importance of re- sponse to neoadjuvant chemotherapy in potentially potentially curable colorectal cancer liver metastases [ J J. BMC Cancer, 2008,8 ( 120 ) : 1- 7.

二级参考文献40

  • 1Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008[J].Int J Cancer,2010,127(2):2893-2917.
  • 2Kemeny N.Presurgical chemotherapy in patients being considered for liver resection[J].The Oncologist,2007,12(7):825-839.
  • 3Khatri VP,Chee KG,Petrelli NJ.Modern multimodality approach to hepatic colorectal metastases:solutions and controversies[J].Surg Oncol,2007,16(1):71-83.
  • 4Nordlinger B,Sorbye H,Glimelius B,et al.Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer(EORTC Intergroup trial 40983):A randomised controlled trial[J].Lancet,2008,371(9617):1007-1016.
  • 5Nordlinger B,Sorbye H,Glimelius B,et al.Perioperative FOLFOX4Chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer(EORTC40983):long-term results of a randomize,controlled,phase 3 trial[J].Lancet Oncol,2013,14(12):1208-1215.
  • 6Adam R,Pascal G,Castaing D,et al.Tumor progression while on chemotherapy:A contraindication to liver resection for multiple colorectal metastases?[J].Ann Surg,2004,240(6):1052-1061.
  • 7Tamandl D,Gruenberger B,Herberger,et al.Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients[J].J Surg Oncol,2009,100(5):364-371.
  • 8Gruenberger B,Scheithauer W,Punzengruber R,et al.Importance of response to neoadjuvant chemotherapy in potentially potentially curable colorectal cancer liver metastases[J].BMC Cancer,2008,8:120.
  • 9Folprecht G,Grothey A,Alberts S,et al.Neoadjuvant treatment of unresectable colorectal liver metastases:Correlation between tumour response and resection rates[J].Ann Oncol,2005,16(8):1311-1319.
  • 10Hind D,Tappenden P,Tumur I,et al.The use of irinotecan,oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer:systematic review and economic evaluation[J].Health Technol Assess,2008,12(15):iii-ix,xi-162.

同被引文献38

  • 1施清泉,周志平,叶超平.31例转移性肝癌手术治疗的预后因素分析[J].重庆医学,2004,33(11):1735-1736. 被引量:3
  • 2迟惠昌,胡凤山.槐耳颗粒联合化学药物动脉灌注治疗转移性肝癌62例[J].中国中医药信息杂志,2005,12(7):69-70. 被引量:7
  • 3董锐增,莫善兢.大肠癌肝转移的治疗进展[J].实用肿瘤杂志,2005,20(4):363-366. 被引量:10
  • 4Woo SR, Fuetes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors[ J]. Immunity,2014,41 (5) :830-842.
  • 5Liao C, Xiao W, Zhu N, et al. Radiotherapy suppressed tumor-specific recruitment of regulator T cells via up-regulating microR-Sd5 in Lewis lung carcinoma ceils[ J ]. Int J Clin Exp Pathol, 2015,8 (3) : 2535- 2544.
  • 6Salama P, Phillips M, Grieu F, et al. Tumor infiltrating FOXP3 + T regulatory cells show strong prognostic significance in eolorectal canc- er[J]. J Clin Oncol,2009,27(2):186-192.
  • 7Curiel TJ. Regulatory T cells and treatment of cancer [ J ]. Curr Opin Immunol, 2008, 20(2) :241-246.
  • 8Ladoire S, Arnould L, Mignot G, et al. Presence of Foxp3 expression in tumor cells predicts better survival in I-IER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy [ J ]. Breast Cancer Res Treat ,2011,125 ( 1 ) :65-72.
  • 9Walker JM, Harrison FE. Shared neuropathological characteristics of o- besity, type 2 diabetes and alzheimer' s disease : impacts on cognitive decline [ J ]. Nutrients ,2015,7 (9) :7332-7357.
  • 10Matsnoka Y, Nishi D, Hamazaki K, et al. Doeosabexaenoic acid for se- lective prevention of posttraumatic stress disorder among severely in- jured patients : a randomized, placebo-controlled trial [ J ]. J Clin Psy- chiatry ,2015,76 ( 8 ) : e1015-e1022.

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部